Navigation Links
GenVec Reports Second Quarter 2009 Financial Results
Date:8/6/2009

rs, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to certain of our product candidates being in early stages of development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

(Tables to Follow)

                                 GenVec, Inc.
                      Condensed Statements of Operations
                     (in thousands, except per share data)

                                   Three Months Ended  Six Months Ended
                                       June 30,             June 30,
                                      2009   2008       2009     2008
                                      ----   -
'/>"/>
SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. GenVec Expands Contract Supporting Malaria Vaccine Program
2. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
3. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
4. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
5. OncoGenex Reports Second Quarter 2009 Financial Results
6. Repligen Reports First Quarter Fiscal Year 2010 Financial Results
7. PDI Reports 2009 Second Quarter Financial Results
8. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
9. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. NxStage Reports Second Quarter 2009 Financial Results
11. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  ECC West Africa, LLC ... with University College Hospital (UCH) Ibadan Board ... project to finance, design, construct, and operate and maintain ... Nigeria . Under the first of the 4-phase ... documents and funding applications. UCH Ibadan intends to finance ...
(Date:7/24/2014)... scientists are making progress in devising suitable means ... relies on quantum dotsa kind of artificial atom, ... new study demonstrates that changing the coupling of ... impulses can help better control them. This has ... quantum information units, which would produce faster quantum ...
(Date:7/24/2014)... -- Research and Markets has announced the ... report to their offering.  ... in vitro growth of plant or animal cells for ... production. Cell culture is a crucial step in tissue ... culture consumables are necessary for the in vitro production ...
(Date:7/24/2014)... 2014 SRI International has been awarded a ... of Allergy and Infectious Diseases (NIAID), part of the ... potential therapies for HIV infection and AIDS. The contract ... AIDS and the complications and opportunistic infections associated with ... transmission of HIV. According to the ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... Adult Cough Products Using ... Technologies, CHESTER, N.J. and SALT LAKE CITY, Sept. ... and Lipocine Inc., a,privately- held, leading drug delivery company ... drug delivery and,therapeutics needs, today announced that they have ...
... Company Enters Into License, Commercialization and Supply Agreement, Company to Host Conference ... ... 2007, LEXINGTON, Mass., Sept. 19 ... AGN ), through its acquisition of Esprit Pharma, has obtained the,United States ...
... Kleiner Perkins ... Strong Endorsement of Technology Pioneer at Forefront of Developing No- ... Compromise Biofuels, ... hydrocarbon biofuels, today,announced that it closed the first tranche of its $70 million ...
Cached Biology Technology:Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement 2Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement 3Indevus Announces Allergan as New Partner for SANCTURA Brand 2Indevus Announces Allergan as New Partner for SANCTURA Brand 3Indevus Announces Allergan as New Partner for SANCTURA Brand 4Indevus Announces Allergan as New Partner for SANCTURA Brand 5Indevus Announces Allergan as New Partner for SANCTURA Brand 6Amyris Biotechnologies Announces $70 Million Series B Round 2
(Date:7/24/2014)... 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, an innovative ... cut emergency room wait times by an average of ... Center, according to a recent study published in the ... using the suite to access data from incoming patients, ... "Using Geneva,s technology platform we have been able ...
(Date:7/24/2014)... average over a 35 year period in which the ... of humans on declining animal numbers. This decline matters ... spiders, crustaceans, slugs and worms bring to our day-to-day ... for nutrient cycling, water filtration and human health. , ... by UCL, Stanford and UCSB, focused on the demise ...
(Date:7/24/2014)... a smog-free Los Angeles, where electric cars ply silent ... on heat from beneath the earth, from howling winds ... Stanford study finds that it is technically and economically ... powered by clean, renewable energy. Published in Energy ... inexpensive and reliable energy supply in California that could ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4
... of Medicine has helped confirm the reliability of a ... the long-promised era of personalized medicine based on each ... the five sites that helped determine that the genetic ... developing cirrhosis from chronic hepatitis C infection. That means ...
... has shown that opening windows and doors provided ventilation ... and 18 times that of rooms with windows and ... Escombe from Imperial College London, compared the airflow in ... rooms, TB wards, respiratory wards, general medical wards, outpatient ...
... lupus, is a complex autoimmune disease marked by ... among other symptoms. Some studies have described a ... psychosis, and a protein autoantibody associated with the ... To investigate how an autoantibody could stimulate behavioral ...
Cached Biology News:New test helps identify hepatitis C patients at high risk of developing cirrhosis 2New test helps identify hepatitis C patients at high risk of developing cirrhosis 3New insights into autoimmunity and depression 2
... loxP-PGK-gb2-neo-loxP template is designed to allow ... cells. The loxP-PGK-gb2-neo-loxP template encodes ... a prokaryotic promoter (gb2) for expression ... a eukaryotic promoter (PGK) for expression ...
... depletion cocktail is tailored to ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... system. The CD4+ T cell ...
Standard Fluka For microscopy (Hist.) redox indicator...
... The VSOS-4 Orbital Shaker is designed ... to provide a uniform motion that is both ... The VSOS-4 Orbital Shaker provides a smooth, quiet, ... for a wide range of laboratory applications such ...
Biology Products: